Last 12 months
Inside the activity.
0 purchase rows · 25 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 5 |
| Mar 2026 | 0 | 12 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 30, 2023 Filed Jul 6, 2023 20:13 UTC |
Ben Arye BarakGeneral Counsel
|
GrantOrdinary Shares | 288 | $35.28 | $10,160.64 |
DisclosureSEC source: 0001562180-23-005758 · primarydocument.xml · nonDerivative · entry 1 Ben Arye Barak · CIK 0001917165 · General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,195 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2023. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 20:13 UTC |
Cordova AshleyChief Financial Officer
|
GrantOrdinary Shares | 367 | $35.28 | $12,947.76 |
DisclosureSEC source: 0001562180-23-005757 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,677 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2023. Read SEC document |
| June 30, 2023 Filed Jul 6, 2023 20:12 UTC |
Danziger AsafDirector · Chief Executive Officer
|
GrantOrdinary Shares | 367 | $35.28 | $12,947.76 |
DisclosureSEC source: 0001562180-23-005755 · primarydocument.xml · nonDerivative · entry 1 Danziger Asaf · CIK 0001654435 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,989 F1 · security: The reporting person is voluntarily reporting the acquisition of shares of the issuer's ordinary shares pursuant to the NovoCure Limited Employee Share Purchase Plan ("ESPP"), for the ESPP purchase period of January1, 2023 through June 30, 2023. This transaction is also exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the issuer's ordinary shares on June 30, 2023. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:05 UTC |
VERNON W ANTHONYDirector
|
GrantStock Option (Right to Buy) · Derivative | 6,277 | $0.00 Strike: $48.66 | $0.00 |
DisclosureSEC source: 0001562180-23-005017 · primarydocument.xml · derivative · entry 2 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,277 Underlying: Ordinary Shares · 6,277 shares Expires 2033-06-06 F2 · derivative.exercise_date: Options to buy 6,277 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:05 UTC |
VERNON W ANTHONYDirector
|
GrantRestricted Stock Units | 3,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005017 · primarydocument.xml · nonDerivative · entry 1 VERNON W ANTHONY · CIK 0001369091 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,797 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:05 UTC |
Scannell Timothy JDirector
|
GrantStock Option (Right to Buy) · Derivative | 6,277 | $0.00 Strike: $48.66 | $0.00 |
DisclosureSEC source: 0001562180-23-005016 · primarydocument.xml · derivative · entry 2 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,277 Underlying: Ordinary Shares · 6,277 shares Expires 2033-06-06 F2 · derivative.exercise_date: Options to buy 6,277 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:05 UTC |
Scannell Timothy JDirector
|
GrantRestricted Stock Units | 3,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005016 · primarydocument.xml · nonDerivative · entry 1 Scannell Timothy J · CIK 0001451533 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,928 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:04 UTC |
Hung DavidDirector
|
GrantStock Option (Right to Buy) · Derivative | 12,554 | $0.00 Strike: $48.66 | $0.00 |
DisclosureSEC source: 0001562180-23-005015 · primarydocument.xml · derivative · entry 1 Hung David · CIK 0001310880 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,554 Underlying: Ordinary Shares · 12,554 shares Expires 2033-06-06 F1 · derivative.exercise_date: Options to buy 12,554 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:04 UTC |
Madden Martin J.Director
|
GrantStock Option (Right to Buy) · Derivative | 12,554 | $0.00 Strike: $48.66 | $0.00 |
DisclosureSEC source: 0001562180-23-005014 · primarydocument.xml · derivative · entry 1 Madden Martin J. · CIK 0001696864 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,554 Underlying: Ordinary Shares · 12,554 shares Expires 2033-06-06 F1 · derivative.exercise_date: Options to buy 12,554 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:04 UTC |
LEUNG GABRIELDirector
|
GrantStock Option (Right to Buy) · Derivative | 6,277 | $0.00 Strike: $48.66 | $0.00 |
DisclosureSEC source: 0001562180-23-005013 · primarydocument.xml · derivative · entry 2 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,277 Underlying: Ordinary Shares · 6,277 shares Expires 2033-06-06 F2 · derivative.exercise_date: Options to buy 6,277 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:04 UTC |
LEUNG GABRIELDirector
|
GrantRestricted Stock Units | 3,853 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-005013 · primarydocument.xml · nonDerivative · entry 1 LEUNG GABRIEL · CIK 0001236183 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,139 F1 · shares: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:04 UTC |
HILLEMAN JERYL LDirector
|
GrantStock Option (Right to Buy) · Derivative | 12,554 | $0.00 Strike: $48.66 | $0.00 |
DisclosureSEC source: 0001562180-23-005012 · primarydocument.xml · derivative · entry 1 HILLEMAN JERYL L · CIK 0001216628 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,554 Underlying: Ordinary Shares · 12,554 shares Expires 2033-06-06 F1 · derivative.exercise_date: Options to buy 12,554 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2024 annual general meeting of shareholders. Read SEC document |
| May 09, 2023 Filed May 11, 2023 20:34 UTC |
Stafford KristinDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,873 | $0.00 Strike: $72.02 | $0.00 |
DisclosureSEC source: 0001562180-23-004074 · primarydocument.xml · derivative · entry 1 Stafford Kristin · CIK 0001970438 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,873 Underlying: Ordinary Shares · 15,873 shares Expires 2033-05-08 F1 · derivative.exercise_date: These stock options will vest in equal parts on the first, second and third anniversary of the grant date. Read SEC document |
| May 09, 2023 Filed May 17, 2023 20:58 UTC Amendment |
Stafford KristinDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,873 | $0.00 Strike: $70.02 | $0.00 |
DisclosureSEC source: 0001562180-23-004210 · primarydocument.xml · derivative · entry 1 Stafford Kristin · CIK 0001970438 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,873 Underlying: Ordinary Shares · 15,873 shares Expires 2033-05-08 F1 · derivative.exercise_price: Incorrectly listed in the original filing. This is the correct amount. F2 · derivative.exercise_date: These stock options will vest in equal parts on the first, second and third anniversary of the grant date. Read SEC document |
| March 07, 2023 Filed Mar 7, 2023 21:52 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 2,315 | $75.59 | $174,999.42 |
DisclosureSEC source: 0001562180-23-002581 · primarydocument.xml · nonDerivative · entry 4 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,284 F3 · price: On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 2,315 shares in multiple trades at prices ranging from $75.33 to $75.94. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 07, 2023 Filed Mar 7, 2023 21:52 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 6,003 | $75.00 | $450,205.79 |
DisclosureSEC source: 0001562180-23-002581 · primarydocument.xml · nonDerivative · entry 3 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,599 F2 · price: On the transaction date, pursuant to a Rule 10b5-1 trading plan adopted by the reporting person, the reporting person sold 6,003 shares in multiple trades at prices ranging from $74.33 to $75.32. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 16:43 UTC |
Weinberg UriChief Innovation Officer
|
GrantOrdinary Shares | 3,936 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002494 · primarydocument.xml · nonDerivative · entry 2 Weinberg Uri · CIK 0001811030 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,044 F1 · shares: Represents vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 16:43 UTC |
Weinberg UriChief Innovation Officer
|
GrantOrdinary Shares | 28,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002494 · primarydocument.xml · nonDerivative · entry 1 Weinberg Uri · CIK 0001811030 · Chief Innovation Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,108 F1 · shares: Represents vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:41 UTC |
Shah PriteshChief Growth Officer
|
GrantOrdinary Shares | 43,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002492 · primarydocument.xml · nonDerivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,220 F2 · shares: Represents vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:41 UTC |
Shah PriteshChief Growth Officer
|
GrantOrdinary Shares | 3,936 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002492 · primarydocument.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,974 F2 · shares: Represents vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:40 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
GrantOrdinary Shares | 3,936 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002491 · primarydocument.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 235,388 F2 · shares: Represents vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:40 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
GrantOrdinary Shares | 48,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002491 · primarydocument.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,452 F2 · shares: Represents vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:40 UTC |
Cordova AshleyChief Financial Officer
|
GrantOrdinary Shares | 11,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002490 · primarydocument.xml · nonDerivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,815 F2 · shares: Represents vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:37 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 2,059 | $77.64 | $159,858.91 |
DisclosureSEC source: 0001562180-23-002489 · primarydocument.xml · nonDerivative · entry 3 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,893 F3 · security: Sold pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 21:37 UTC |
Leonard Frank XPresident, CNS Cancers US
|
GrantOrdinary Shares | 11,808 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-23-002489 · primarydocument.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,952 F2 · shares: Represents vesting of performance-based restricted stock units. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 16:50 UTC |
Burke William PatrickChief Human Resources Officer
|
SaleOrdinary Shares | 593 | $76.16 | $45,162.52 |
DisclosureSEC source: 0001562180-23-002577 · primarydocument.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,090 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:52 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 888 | $76.16 | $67,629.55 |
DisclosureSEC source: 0001562180-23-002581 · primarydocument.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,602 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:52 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 4,403 | $76.16 | $335,329.84 |
DisclosureSEC source: 0001562180-23-002581 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,490 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:52 UTC |
Shah PriteshChief Growth Officer
|
SaleOrdinary Shares | 16,909 | $76.16 | $1,287,779.29 |
DisclosureSEC source: 0001562180-23-002580 · primarydocument.xml · nonDerivative · entry 3 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,799 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:52 UTC |
Shah PriteshChief Growth Officer
|
SaleOrdinary Shares | 2,942 | $76.16 | $224,060.95 |
DisclosureSEC source: 0001562180-23-002580 · primarydocument.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 141,708 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:52 UTC |
Shah PriteshChief Growth Officer
|
SaleOrdinary Shares | 1,570 | $76.16 | $119,570.26 |
DisclosureSEC source: 0001562180-23-002580 · primarydocument.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,650 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:51 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
SaleOrdinary Shares | 20,415 | $76.16 | $1,554,794.15 |
DisclosureSEC source: 0001562180-23-002579 · primarydocument.xml · nonDerivative · entry 3 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,753 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:51 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
SaleOrdinary Shares | 1,692 | $76.16 | $128,861.70 |
DisclosureSEC source: 0001562180-23-002579 · primarydocument.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,168 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:51 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
SaleOrdinary Shares | 3,528 | $76.16 | $268,690.36 |
DisclosureSEC source: 0001562180-23-002579 · primarydocument.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,860 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:51 UTC |
Cordova AshleyChief Financial Officer
|
SaleOrdinary Shares | 775 | $76.16 | $59,023.54 |
DisclosureSEC source: 0001562180-23-002578 · primarydocument.xml · nonDerivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,310 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 03, 2023 Filed Mar 7, 2023 21:51 UTC |
Cordova AshleyChief Financial Officer
|
SaleOrdinary Shares | 4,730 | $76.16 | $360,233.96 |
DisclosureSEC source: 0001562180-23-002578 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,085 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:13 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 308 | $76.05 | $23,423.74 |
DisclosureSEC source: 0001562180-23-002359 · primarydocument.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,988 F2 · price: On March 2, 2023 pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leonard, Mr. Leonard sold 308 shares in multiple trades at prices ranging from $75.95 to $76.14. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:13 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 3,799 | $75.32 | $286,153.98 |
DisclosureSEC source: 0001562180-23-002359 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,296 F1 · price: On March 2, 2023 pursuant to a Rule 10b5-1 trading plan adopted by Mr. Leonard, Mr. Leonard sold 3,799 shares in multiple trades at prices ranging from $74.89 to $75.88. The price reported above reflects the weighted average sale price. Mr. Leonard hereby undertakes to provide to the Staff, the issuer for any security holder of the issuer, upon request, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 16:42 UTC |
Burke William PatrickChief Human Resources Officer
|
SaleOrdinary Shares | 281 | $75.28 | $21,153.09 |
DisclosureSEC source: 0001562180-23-002493 · primarydocument.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,683 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:41 UTC |
Shah PriteshChief Growth Officer
|
SaleOrdinary Shares | 937 | $75.28 | $70,535.39 |
DisclosureSEC source: 0001562180-23-002492 · primarydocument.xml · nonDerivative · entry 1 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,038 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:40 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
SaleOrdinary Shares | 1,213 | $75.28 | $91,312.09 |
DisclosureSEC source: 0001562180-23-002491 · primarydocument.xml · nonDerivative · entry 1 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,402 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:40 UTC |
Cordova AshleyChief Financial Officer
|
SaleOrdinary Shares | 1,055 | $75.28 | $79,418.18 |
DisclosureSEC source: 0001562180-23-002490 · primarydocument.xml · nonDerivative · entry 1 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,007 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:37 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 844 | $75.28 | $63,534.55 |
DisclosureSEC source: 0001562180-23-002489 · primarydocument.xml · nonDerivative · entry 1 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,144 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 16:51 UTC |
Burke William PatrickChief Human Resources Officer
|
SaleOrdinary Shares | 755 | $76.36 | $57,653.61 |
DisclosureSEC source: 0001645113-23-000026 · wf-form4_167779384761589.xml · nonDerivative · entry 2 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,964 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:01 UTC |
Leonard Frank XPresident, CNS Cancers US
|
SaleOrdinary Shares | 1,684 | $76.36 | $128,594.28 |
DisclosureSEC source: 0001645113-23-000031 · wf-form4_167779444622406.xml · nonDerivative · entry 2 Leonard Frank X · CIK 0001822879 · President, CNS Cancers US 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,095 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 22:00 UTC |
Shah PriteshChief Growth Officer
|
SaleOrdinary Shares | 1,923 | $76.36 | $146,844.90 |
DisclosureSEC source: 0001645113-23-000030 · wf-form4_167779437669900.xml · nonDerivative · entry 2 Shah Pritesh · CIK 0001744884 · Chief Growth Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,975 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:55 UTC |
Cordova AshleyChief Financial Officer
|
SaleOrdinary Shares | 2,198 | $76.36 | $167,844.56 |
DisclosureSEC source: 0001645113-23-000027 · wf-form4_167779410749716.xml · nonDerivative · entry 2 Cordova Ashley · CIK 0001822014 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,062 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units listed. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 01, 2023 Filed Mar 2, 2023 21:49 UTC |
GROENHUYSEN WILHELMUS CMChief Operating Officer
|
SaleOrdinary Shares | 2,164 | $76.36 | $165,248.23 |
DisclosureSEC source: 0001645113-23-000025 · wf-form4_167779374758834.xml · nonDerivative · entry 2 GROENHUYSEN WILHELMUS CM · CIK 0001264783 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 184,615 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the Restricted Stock Units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 16:51 UTC |
Burke William PatrickChief Human Resources Officer
|
GrantOptions to Buy Ordinary Shares · Derivative | 20,168 | $76.97 Strike: $76.97 | $1,552,330.96 |
DisclosureSEC source: 0001645113-23-000026 · wf-form4_167779384761589.xml · derivative · entry 3 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,168 Underlying: Ordinary Shares · 20,168 shares Expires 2033-02-27 F3 · derivative.exercise_date: Options to buy 20,168 ordinary shares will vest and become exercisable in equal installments on each of February 28, 2024, 2025, 2026 and 2027, subject to the reporting person's continued employment through such dates. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 16:51 UTC |
Burke William PatrickChief Human Resources Officer
|
GrantOrdinary Shares | 12,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001645113-23-000026 · wf-form4_167779384761589.xml · nonDerivative · entry 1 Burke William Patrick · CIK 0001880493 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,719 F1 · shares: Represents restricted share units that are scheduled to vest in equal installments on February 28, 2024, 2025 and 2026, subject to the reporting person's continued employment through such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.